Pregled bibliografske jedinice broj: 724625
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial // The Lancet, 377 (2011), 9782; 2013-2022 doi:10.1016/S0140-6736(11)60600-4 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 724625 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
Autori
Bousser, Marie-Germaine ; Amarenco, Pierre ; Chamorro, Angel ; Fisher, Marc ; Ford, Ian ; Fox, Kim M. ; Hennerici, Michael G. ; Mattle, Heinrich P. ; Rothwell, Peter M. ; de Cordouee, Agnes ; Fratacci, Marie-Dominique
Izvornik
The Lancet (0140-6736) 377
(2011), 9782;
2013-2022
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
terutroban; aspirin; secondary stroke prevention
Sažetak
The trial showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- MEDLINE
